Table 2.
Lipidomic analysis.
| Group | Free AA | Free EPA | Free DHA | AT-LXA4 | LXA4 | RvD1 |
|---|---|---|---|---|---|---|
| S-Control | 17.84 | 0.52 | 6.02 | ND | ND | ND |
| S-EVs #2 | 28.86 | 0.72 | 10.34 | ND | ND | ND |
| S-EVs #3 | 50.02 | 2.20 | 19.62 | 1.56 | 55.40 | 15.44 |
| S-EVs #4 | 6,370.88 | 4,764.42 | 5,149.18 | 20.26 | 24.46 | ND |
| S-EVs #5 | 5,872.28 | 4,633.08 | 5,625.40 | 13.36 | 15.94 | ND |
| L-Control | 154.54 | 94.24 | 110.38 | ND | ND | ND |
| L-EVs #2 | 73.98 | 38.58 | 47.52 | ND | ND | ND |
| L-EVs #3 | 25.28 | 12.64 | 13.92 | 6.26 | 207.34 | 70.70 |
| L-EVs #4 | 3,596.42 | 2,707.80 | 3,438.06 | 8.00 | 9.14 | ND |
| L-EVs #5 | 2,183.12 | 2,387.16 | 2,393.28 | 7.36 | 9.24 | ND |
Incorporation of fatty acids and pro-resolving mediators by HEI-OC1 EVs. S-Control: S-EVs untreated; S-EVs #2: S-EVs incubated with 10 mM ASP; S-EVs #3: S-EVs incubated with 10 mM LXA4 + 10 mM RvD1; S-EVs #4: S-EVs incubated with 10 mM AA+EPA+DHA+LA; S-EVs #5: S-EVs incubated with 10 mM AA+EPA+DHA+LA+ASP; L-Control: L-EVs untreated; L-EVs #2: L-EVs incubated with 10 mM ASP; L-EVs #3: L-EVs incubated with 10 mM LXA4+RvD1; L-EVs #4: L-EVs incubated with 10 mM AA+EPA+DHA+LA; L-EVs #5: L-EVs incubated with 10 mM AA+EPA+DHA+LA+ASP. Results are expressed in pmol/ml. ND, Not Detected.